Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

por Weghuber, Daniel, Boberg, Klaus, Hesse, Dan, Jeppesen, Ole K, Sørrig, Rasmus, Kelly, Aaron S
Publicado 2022

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

por Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina
Publicado 2020

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

por Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Publicado 2021

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)

por Rahman, Syed Kasfur, Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Publicado 2022

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

por Bain, Stephen C., Mosenzon, Ofri, Arechavaleta, Rosario, Bogdański, Pawel, Comlekci, Abdurrahman, Consoli, Agostino, Deerochanawong, Chaicharn, Dungan, Kathleen, Faingold, Maria C., Farkouh, Michael E., Franco, Denise R., Gram, Jeppe, Guja, Cristian, Joshi, Pankaj, Malek, Rachid, Merino‐Torres, Juan F., Nauck, Michael A., Pedersen, Sue D., Sheu, Wayne H. ‐H., Silver, Robert J., Tack, Cees J., Tandon, Nikhil, Jeppesen, Ole K., Strange, Mette, Thomsen, Mette, Husain, Mansoor
Publicado 2018